Compare American States Water Company (AWR) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? American States Water Company trades at $87.53 (market cap $3.47B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.7× American States Water Company's market cap, and American States Water Company pays a 2.49% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AWR | BIO | |
|---|---|---|
Market Cap | $3.47B | $9.43B |
Sector | Utilities | Health |
52-Week High | $89.28 | $356.25 |
52-Week Low | $70.10 | $241.71 |
Enterprise Value | $4.37B | $9.18B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $87.83, up 1.46% today, with strong technical momentum as moving averages signal bullish alignment. The company maintains robust fundamentals with 20.52% net income margin and consistent dividend growth, recently increasing its quarterly payout by 8.2%. Recent Q2 2026 earnings beat expectations at $1.09 per share, driven by water rate increases and operational gains across business segments.
Outlook remains stable with revenue growth and dividend reliability, though valuation multiples appear elevated versus utilities peers. Key risks include regulatory dependence on rate approvals and competitive pressures. Analyst sentiment is mixed with 20% buy ratings amid concerns about current price levels relative to earnings potential.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
